Facts & Figures

Science for a better life - Medical Progress for the Benefit of the Patient

From world-renowned pharmaceutical products to high-tech platforms, from innovative diagnostics technologies to veterinary medicines – Bayer HealthCare is a globally researching healthcare company and develops products of the divisions Animal Health, Bayer Schering Pharma, Consumer Care and Diabetes Care.

Facts and Figures at a glance


Research expenses 2009	1,847€ million (2008: 1,742 € million)
Proportion of total Bayer group research expenses 2009	67,3%
Employees in Research & Development	6,941 (as of Dec. 31, 2009)
Main research locations	Berlin and Wuppertal, Germany and Berkeley, USA
Research focus	Berlin: Diagnostic Imaging, Oncology, Women’s Healthcare Wuppertal: Hematology, Cardiology, Oncology Berkeley: Biologics

Research activities 2009

In 2009 we invested €1,847 million (2008: €1,742 million) in research and development in the Pharmaceuticals and Consumer Health segments to lay the foundations for the introduction of further innovative products in the subgroup’s expanding markets. This represented about 67,3 percent of the Bayer Group’s entire research and development expenditures and was equivalent to 11.6 percent of sales.

Research and development in the Pharmaceuticals segment is strategically aligned to the conditions in its markets. In drug discovery we focus on four growth areas: diagnostic imaging, cardiology, oncology, and women’s healthcare. The respective research activities and capacities are concentrated at three sites in Berlin and Wuppertal, Germany, and Berkeley, California. Work at the Berlin and Wuppertal sites focuses on identifying molecular targets in order to develop and optimize lead substances. Research is also carried out at these sites in the fields of drug metabolism, pharmacokinetics, toxicology and clinical pharmacology. Berkeley is an important global research and development center for protein-based active ingredients and is home to the biotechnological production facility for Kogenate®.

Research locations

The Berlin and Wuppertal locations have significant capabilities and activities in the identifi cation of molecular targets and the development and optimization of lead substances, as well as in drug metabolism, pharmacokinetics, toxicology and clinical pharmacology.

Berkeley is an important global research and development center for protein-based active ingredients and is home to the biotechnological production facility for Kogenate®. Bayer HealthCare’s u.s. research sites in West Haven, Connecticut, and Richmond, California, have been or will be closed.